Advanced searches left 3/3

Arthritis - Springer Nature

Summarized by Plex Scholar
Last Updated: 10 June 2022

* If you want to update the article please login/register

Gait analysis and knee joint kinematics before a and 6 month after of corrective valgus osteotomy at patients with medial knee arthritis

"Purpose A varus deformity of the lower legs results in increased loading of the medial compartment of the knee joint, contributing to knee joint degenerative changes and eventually to joint osteoarthritis. The aim of the study was to determine the mid-term changes in gait biomechanics and clinical signs in patients with VD of KJ and OA before and after surgical correction. According to Kellgren-Lawrence, the trial included 25 patients with medial OA of grade 2–u20133 who underwent knee joint osteotomy followed by corrective osteotomy. Conclusions According to our estimates, there was a statistically significant post-operative rise in the knee extension amplitude by 1. 4 u00b0 in female patients and no increase in male patients. After surgery, we observed a total of three changes in the KJ kinematics, a decrease extension amplitude in both KJs, and first flexion amplitudes in both KJs. Conclusions According to our report, the midterm results after a valgus osteotomy revealed clinical improvements based on the VAS and KOOS scores, but they were less apparent than in longer-term studies after surgery. "As the function of the operated joint is concerned, valgus osteotomy regained walking gait with improved first and second flexion amplitudes, as the operation's function was unclear.

Source link: https://doi.org/10.1007/s00264-022-05370-9


Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab

"Introduction In phase 3 trials with secukinumab in both psoriatic arthritis and ankylosing spondylitis have demonstrated sustained improvement in clinical outcomes. " Patients with PsA and AS were surveyed for the purpose, retention rates, and safety of secukinumab in patients with PsA and AS. According to PsA and AS, respectively, overall secukinumab retention rates in patients with PsA and AS were 74. 9 and 78. 9% after enrolment. Patients with PsA and BASDAI scores [3. 3 vs. 2. 9] in patients with AS [3. 2 vs. 2. 9 ] indicate long-term benefit for patients on secukinumab for at least two years after enrolment. Conclusions Secukinumab's More than two years since its inception, secukinumab's high retention rates and positive safety profile, as well as ongoing success in patients undergoing secukinumab therapy.

Source link: https://doi.org/10.1007/s40744-022-00460-x


Correlates of physical activity in adults with spondyloarthritis and rheumatoid arthritis: a systematic review

"Physical therapy is a common non-pharmacological therapy option for those suffering from rheumatoid arthritis and spondyloarthritis. " The objective of this systematic literature review was to summarize and present updated synthesis of the causes associated with PA in the RA and SpA populations. The inclusion criteria were met for Forty RA and eleven SpA articles. In no RA study, environmental variables were not included. Positive results were found between PA and high-density lipoprotein, self-confidence, and motivation in individuals living with RA. Continuous negative correlations with functional impairment were found in individuals with SpA, consistent positive links were found between PA and quality of life, and consistent negative correlations with functional disability. In those living with RA and SpA, the most consistent factors are physical and psychological factors. To fully understand the contributing factors that contribute to PA in these populations, especially in those living with SpA," studies with prospective designs are required to better understand the causes associated with PA in these populations, especially those living with SpA. ".

Source link: https://doi.org/10.1007/s00296-022-05142-z


Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

"Introduction/Objectives": "Introduction/Objectives: Objectives The goal of this study is to determine the three-year effectiveness and safety of ixekizumab, as well as without concomitant conventional disease-modifying antirheumatic drug use in patients with active psoriatic arthritis. Patients with PsA who were biologic-nau00efve or had poor response to tumor necrosis factor inhibitors were scheduled to receive 80-mg ixekizumab every four weeks after receiving 160-mg ixekizumab at baseline. Result: (notice) 5. 6 percent, 61. 0 percent, and 66. 1 percent of ixekizumab-treated patients, with 59. 1%, 67. 0%, and 61% of ixekizumab-treated patients improving by 20% in the American College of Rheumatology scale scores at week 156. Ixekizumab demonstrated long-term success in treating patients with PsA for up to three years in monotherapy or in combination with MTX or another csDMARD. Patients with active PsA can have improved clinical results over time with Ixekizumab monotherapy or in combination with concomitant MTX or any concomitant csDMARD in patients with active PsA. In the subgroups of patients receiving ixekizumab monotherapy or other csDMARDs, the Ixekizumab monotherapy has similar radiographic stability as ixekizumab with MTX or ixekizumab with other csDMARDs; similar reduction of radiographic progression was seen between the patients receiving ixekizumab monotherapy or other csDMARDs; similar inhibition of radiographic progression was observed in patients receiving xekizumab cs receiving ixekizumab monotherapy or other csDMARDs: csDMARDs, cs, pharmacs cs csDMARDs, cs xekizumab monotherapy or csam cs csDMARDs with cs. u2022 A long-term safety profile of ixekizumab used as monotherapy or in combination with MTX or other csDMARDs is consistent with what has been reported. The addition of MTX or other csDMARD to ixekizumab therapy did not have a detrimental long-term safety profile of ixekizumab. ".

Source link: https://doi.org/10.1007/s10067-022-06218-8


Oral methotrexate at doses 15–25 mg/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

"Objective": "Objective" is a word that describes the most effective method of methotrexate therapy for rheumatoid arthritis treatment has yet to be established. In adult patients with RA, our aim was to compare the efficacy, safety, and bioavailability profiles of oral MTX with parental MTX. In addition, parenteral MTX provided a significant boost in AUC_0-t's value, but not in C _max and T _max compared to oral MTX. Oral MTX in active RA is not inferior to parenteral in terms of effectiveness and safety, with doses of 15-30 mg/week.

Source link: https://doi.org/10.1007/s10067-022-06221-z


Prediction of hidden patterns in rheumatoid arthritis patients records using data mining

"Rheumatoid Arthritis disease is an inflammatory disease that is characterized by persistent synovitis and autoantibodies, which lead to joint damage and reduced quality of life. " This paper investigates the most significant characteristics that correlated with RA disease prevalence: two data mining techniques to investigate the most common characteristics that are correlated with RA disease prevalence: Predictive rules, Feature weight, and Trees algorithms. Many new rules were discovered by using the association's rules algorithms Predictive-Apriori technique. The model will enable RA patients to have will monitored and low disease risk reduction. ".

Source link: https://doi.org/10.1007/s11042-022-13331-y


Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA

"Objective" is a term used to describe treatment characteristics and incidence of inadequate response among patients with ankylosing spondylitis and psoriatic arthritis in the United States. Methods Adult patients with AS or PsA who started advanced therapy were identified from the HealthCore Integrated Research Database, U00ae. The key predictor of inadequate response in patients with AS and PsA was poor adherence. Prior exposure to TNFi was correlated with 3. 89- and 2. 14-fold greater odds of poor response in both AS and PsA patients, respectively, while patients using methotrexate were less likely to have poor responses. PsA's patients, including AS and 77%, had no response to their index advanced therapy within a year after its inception. "Understanding responders in AS and PsA are ineffective, according to the Health and Welfare Departments, who report findings that are useful to identify poor responders in AS and PsA. ".

Source link: https://doi.org/10.1007/s10067-022-06230-y


Real-world single-centre experience of rheumatoid arthritis patients requiring four or more higher cost drugs: response and duration of treatment

"Abstract" is a term used in the United States for people with rheumatoid arthritis. Some consumers of services for people with rheumatoid arthritis doubt the cost-effectiveness of higher cost drugs after several failures are contested by some purchasers of rheumatoid arthritis. We were curious to investigate how HCDs could be used outside of the third choice to record response rates and treatment durations. Method Data From our multi-disciplinary team meeting that is used to determine the use of HCDs were used to identify all RA patients who had been exposed to four or more HCDs. Patients who had responded to one specific drug were more likely to respond to the next. Patients are often affected by late choice HCDs, which is a common result. U2022 Less than 2% of our RA patients needed 4 or more expensive drugs, despite the fact that they were less than 2%. u2022 the fourth generation to sixth choice drugs still worked in 5 to 55% of patients. ".

Source link: https://doi.org/10.1007/s10067-022-06232-w

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions